Clinical trial
CNI-1493 for Treatment of Moderate to Severe Crohn's Disease
NCT00038766 · Ferring Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00038766 |
|---|---|
| Title | CNI-1493 for Treatment of Moderate to Severe Crohn's Disease |
| Official title | A Randomized, Double-Blind, Placebo-controlled Study of CNI-1493 for Treatment of Moderate to Severe Crohn's Disease |
| Acronym | CD02 |
| Lead sponsor | Ferring Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Crohn Disease |
| Intervention type | Drug |
| Interventions | semapimod, placebo |
| Enrollment | 33 |
| Start date | Jun 1, 2002 |
| Primary completion | Jun 1, 2003 |
| Completion | Jun 1, 2003 |
| First posted | Jun 7, 2002 |
| Last update posted | Aug 23, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: